[ad_1]
Debevoise & Plimpton LLP is advising JP Morgan as co-financial advisor to Horizon Therapeutics plc (NASDAQ: HZNP) in its $28.5 billion sale to Amgen. For extra info, please see the corporate’s press launch.
Horizon Therapeutics is a world biotechnology firm headquartered in Dublin, Eire, and is targeted on the invention, growth and commercialization of medicines that handle vital wants for folks impacted by uncommon, autoimmune and extreme inflammatory ailments. Amgen is a extremely targeted biotechnology firm dedicated to unlocking the potential of biology for sufferers affected by severe sicknesses by discovering, creating, manufacturing and delivering modern human therapeutics.
The Debevoise staff is led by M&A associate Andrew Bab and consists of affiliate Colin O’Neal.
[ad_2]
Source link